Two Sigma Investments’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.8M Buy
178,418
+63,706
+56% +$14.1M 0.03% 607
2025
Q4
$26.2M Sell
114,712
-48,464
-30% -$11M 0.04% 594
2025
Q3
$37.8M Sell
163,176
-92,700
-36% -$18.9M 0.06% 403
2025
Q2
$47.5M Buy
255,876
+243,758
+2,012% +$45.3M 0.08% 297
2025
Q1
$2.54M Buy
12,118
+6,418
+113% +$1.25M 0.01% 1588
2024
Q4
$1.01M Sell
5,700
-1,700
-23% -$313K ﹤0.01% 2171
2024
Q3
$1.46M Sell
7,400
-9,672
-57% -$1.81M ﹤0.01% 1872
2024
Q2
$2.93M Sell
17,072
-660,582
-97% -$109M 0.01% 1305
2024
Q1
$123M Sell
677,654
-164,027
-19% -$28.3M 0.29% 82
2023
Q4
$130M Sell
841,681
-62,510
-7% -$9.11M 0.3% 75
2023
Q3
$135M Sell
904,191
-932,692
-51% -$137M 0.36% 63
2023
Q2
$247M Buy
1,836,883
+1,203,543
+190% +$176M 0.62% 8
2023
Q1
$101M Buy
633,340
+460,920
+267% +$70.5M 0.29% 89
2022
Q4
$27.9M Buy
+172,420
New +$26.4M 0.09% 268
2022
Q2
Sell
-900,337
Closed -$146M 2446
2022
Q1
$146M Sell
900,337
-1,025,909
-53% -$149M 0.43% 40
2021
Q4
$261M Buy
1,926,246
+1,057,631
+122% +$125M 0.56% 6
2021
Q3
$93.7M Sell
868,615
-1,242,706
-59% -$142M 0.21% 120
2021
Q2
$238M Sell
2,111,321
-288,876
-12% -$32.5M 0.54% 16
2021
Q1
$260M Buy
2,400,197
+36,559
+2% +$3.91M 0.68% 4
2020
Q4
$253M Sell
2,363,638
-495,317
-17% -$47.6M 0.73% 9
2020
Q3
$250M Buy
2,858,955
+1,069,700
+60% +$101M 0.89% 8
2020
Q2
$176M Buy
1,789,255
+551,553
+45% +$48.6M 0.87% 16
2020
Q1
$94.3M Buy
1,237,702
+202,928
+20% +$17.3M 0.77% 15
2019
Q4
$91.6M Sell
1,034,774
-1,340,930
-56% -$111M 0.28% 69
2019
Q3
$180M Buy
2,375,704
+464,722
+24% +$31.9M 0.61% 12
2019
Q2
$139M Sell
1,910,982
-382,634
-17% -$30.1M 0.46% 28
2019
Q1
$185M Buy
2,293,616
+2,282,042
+19,717% +$187M 0.6% 8
2018
Q4
$1.07M Sell
11,574
-144,726
-93% -$12.7M ﹤0.01% 1618
2018
Q3
$14.8M Sell
156,300
-1,337,531
-90% -$127M 0.04% 505
2018
Q2
$138M Buy
1,493,831
+399,536
+37% +$39M 0.41% 29
2018
Q1
$104M Buy
1,094,295
+964,581
+744% +$106M 0.34% 59
2017
Q4
$12.5M Sell
129,714
-22,571
-15% -$2.13M 0.04% 519
2017
Q3
$13.5M Buy
+152,285
New +$11.6M 0.05% 419
2017
Q2
Sell
-1,206,865
Closed -$81.1M 2904
2017
Q1
$78.6M Sell
1,206,865
-126,159
-9% -$7.93M 0.26% 77
2016
Q4
$83.5M Sell
1,333,024
-1,409,789
-51% -$86.1M 0.32% 60
2016
Q3
$173M Buy
2,742,813
+765,428
+39% +$49.6M 0.63% 13
2016
Q2
$122M Buy
1,977,385
+37,402
+2% +$2.28M 0.53% 26
2016
Q1
$111M Sell
1,939,983
-906,152
-32% -$50.5M 0.53% 27
2015
Q4
$169M Sell
2,846,135
-247,013
-8% -$14.2M 0.81% 4
2015
Q3
$168M Buy
3,093,148
+3,018,258
+4,030% +$196M 0.86% 4
2015
Q2
$5.03M Sell
74,890
-268,343
-78% -$17.5M 0.02% 724
2015
Q1
$20.1M Sell
343,233
-1,562,446
-82% -$94.4M 0.09% 270
2014
Q4
$125M Buy
1,905,679
+1,801,332
+1,726% +$114M 0.69% 13
2014
Q3
$6.03M Sell
104,347
-2,395,248
-96% -$133M 0.03% 576
2014
Q2
$141M Buy
2,499,595
+1,044,030
+72% +$54.8M 0.64% 14
2014
Q1
$74.8M Buy
1,455,565
+371,013
+34% +$18.8M 0.4% 49
2013
Q4
$57.3M Sell
1,084,552
-779,119
-42% -$38.3M 0.32% 68
2013
Q3
$83.4M Buy
1,863,671
+1,426,368
+326% +$63.2M 0.53% 38
2013
Q2
$18.1M Buy
+437,303
New +$19.1M 0.13% 221

Other funds holding ABBV

Two Sigma Investments's ABBV Position: Q1 2026 in Review

Two Sigma Investments increased its AbbVie (ABBV) stake by 56% in Q1 2026, buying an estimated $14.1M and bringing the position to 178,418 shares worth $38.8M. The position accounts for 0.03% of the portfolio, ranked #607.

Two Sigma Investments first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $261M in Q4 2021. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Two Sigma Investments held 178,418 shares of AbbVie worth $38.8M as of Q1 2026.
  • Two Sigma Investments bought 63,706 AbbVie shares in Q1 2026, an estimated $14.1M.
  • AbbVie made up 0.03% of Two Sigma Investments's portfolio in Q1 2026, its #607 holding.
  • Two Sigma Investments first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
  • Two Sigma Investments's AbbVie position peaked at $261M in Q4 2021.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.